With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > REGULATORY
REGULATORY
- 1st Topical JAK Inhibitor Up for MHLW Panel Review Oct. 25, Ono’s Cachexia Drug Still Shelved
October 15, 2019
- MHLW Orphan Status Dropped for Actemra, Rifampicin
October 15, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
- Self-Medication Tax Break Not a Clear-Cut System, Needs More Awareness: LDP Lawmakers
October 11, 2019
- Chuikyo Wary about Further Reduction in Generic Entry Prices
October 10, 2019
- Japan Doctor, Pharmacist Groups Oppose Delisting of OTC-Like Drugs: LDP Taskforce
October 10, 2019
- Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
- CEFP Discussions on Reform Timeline Update Get Underway
October 10, 2019
- As HIF-PH Inhibitor Debut Looms, MHLW Eyes New Medical Fee Schedule for Renal Anemia
October 10, 2019
- MHLW Kicks Off Discussions to Spur Genomic Medicine for Intractable Diseases
October 9, 2019
- Health Minister Keen on Passage of PMD Law Amendment in Extra Diet Session
October 8, 2019
- As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
October 7, 2019
- PMDA Reviewing Safety Risks for Takecab Products and More
October 7, 2019
- MOF Panel Kicks Off FY2020 Budget Debate, Prods Discussions on “Benefits and Burdens”
October 4, 2019
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- MHLW Panel Members Call for Discussion on Range of Health Coverage
September 30, 2019
- Rotavirus Vaccines Added to Public Vaccination Programs from Oct. 1, 2020: MHLW Panel
September 30, 2019
- Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019
- MHLW Orders Label Revisions for Actemra, Tagrisso, Olumiant and More
September 25, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…